课题基金 / 基金详情

Local fibrinolytic activity : an index of biological malignancy in digestive tract Cancers

Local fibrinolytic activity : an index of biological malignancy in digestive tract Cancers
局部纤溶活性:消化道癌症生物恶性肿瘤的指标
批准号:
04670776
负责人:
SHIBATA Junsuke
金额:
$1.47万
依托单位国家:
日本
项目类别:
Grant-in-Aid for General Scientific Research (C)
财政年份:
1992
资助国家:
日本
项目状态:
已结题
起止时间:
1992 至 1993

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
我们对111例胃癌和145例结肠癌患者进行了尿激酶型纤溶酶原激活物(u-PA)、纤溶酶原激活物抑制剂(PAI)-1和PAI-2的免疫组化定位。u-PA在胃癌细胞(44/111,39.6%)和结肠癌细胞(48/145,33.1%)中进行免疫染色,原位杂交证实mRNA在癌细胞中表达。u-PA在肿瘤周围的表达比在中心区域的表达更明显。u-PA阳性患者的5年生存率明显低于u-PA阴性患者(胃癌51.0% VS 77.5%,结肠癌60.2% VS 80.9%)。结肠癌细胞周围成纤维细胞中检测到PAI-1抗原(33/73)。在这些病例中,淋巴结转移似乎低于PAI-1阴性病例。胃癌细胞(47/111,42.3%)和结肠癌细胞(33/73,45.2%)均有PAI-2抗原染色。PAI-2染色强度均匀穿透肿瘤,与u-PA染色模式不同。临床中,u-PA阴性和PAI-2阳性的5年生存率预后较好,而u-PA阳性和PAI-2阴性的5年生存率预后较差(胃癌为81.8%比26.7%,结肠癌为90.9%比53.3%)。这些发现表明,u-PA是由癌细胞自身产生的,与癌细胞的侵袭转移有关,可能是一种生物恶性肿瘤的指标,PAI-1和PAi-2可能在胃癌和结肠癌中具有抑制作用。
英文摘要
We examined immunohistochemically the localization of urokinase-type plasminogen activator(u-PA), plasminogen activator inhibitor(PAI)-1 and PAI-2 in both 111cases of gastric and 145 cases of colon cancer.u-PA was immunostained in both gastric(44/111,39.6%)and colon (48/145,33.1%)cancer cells, confirmed the expression of mRNA in cancer cells using in situ hybridization. The expression of u-PA was more marked at the periphery of the tumor rather than in the central area. The five year survival of patients with u-PA positive was significantly lower than that of patients with u-PA negative (51.0% VS 77.5% in gastric cancer, 60.2% VS 80.9% in colon cancer).PAI-1 antigen was detected in fibroblast cells (33/73)surroundings colon cancer cells. In these cases, lymph node metastasis seemed to be lower than that in PAI-1 negative cases. PAI-2 antigen was stained in both gastric (47/111,42.3%)and colon (33/73,45.2%)cancer cells. The intensity of PAI-2 staining was homogenously through the tumor, different pattern with that of u-PA staining. Clinically, u-PA negative and PAI-2 positive cases disclosed relatively well prognosis in five-year survival rate, whereas u-PA positive and PAI-2 negative cases showed poorer prognosis (81.8% VS 26.7% in gastric cancer, 90.9% VS 53.3% in colon cancer).These findings indicates that u-PA is produced by cancer cells themselves, related to cancer invasion and metastasis, presumably useful for an index of biological malignancy, and PAI-1 and PAi-2 may have inhibitory effects in gastric and colon cancer.
期刊论文(8)
专著(0)
科研奖励(0)
会议论文
Hiroyuki Naitoh: "Expression and Clinical valu of Urokinase-type Plasminogen Activater and Plasminogen Activator Inhibitor-2 in Gastric Cancer" Int.J.Cancer. (in submit).
Hiroyuki Naitoh:“尿激酶型纤溶酶原激活剂和纤溶酶原激活剂抑制剂 2 在胃癌中的表达和临床价值”Int.J.Cancer。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Hiroyuki Naitoh: "Localization of Urokinase-type Plasminogen Activator, Plasminogen Activator Inhibitor-1,2 and Plasminogen in Colon Cancer" Jpn.J.Cancer Res.86. 48-56 (1995)
Hiroyuki Naitoh:“结肠癌中尿激酶型纤溶酶原激活剂、纤溶酶原激活剂抑制剂 1,2 和纤溶酶原的定位”Jpn.J.Cancer Res.86。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Hiroyuki Naitoh: "Localization of Urokinase-type Olasmlnogen Activator,Plasminogen Activator Inhibitor-1,2 and Plasminogen in Colon Cancer" JPN.J.Cancer.Res.86. 48-56 (1995)
Hiroyuki Naitoh:“尿激酶型纤溶酶原激活剂、纤溶酶原激活剂抑制剂-1,2和纤溶酶原在结肠癌中的定位”JPN.J.Cancer.Res.86。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Hiroyuki Naitoh: "Expression and Clinical Value of Urokinase-type Plasminogen Activator Inhibitor-2 in Gastric Canscer" Int.J.Cancer. (in submit).
Hiroyuki Naitoh:“尿激酶型纤溶酶原激活物抑制剂 2 在胃癌中的表达和临床价值”Int.J.Cancer。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
海外基金